07:06 EDT Akero Therapeutics (AKRO) sees cash, equivalents funding operating plan into 2028
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
- Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
- Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
- Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
- Akero Therapeutics reports results from Phase 2b SYMMETRY trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue